Showing posts with label IP protections. Show all posts
Showing posts with label IP protections. Show all posts

Wednesday, April 16, 2025

Why Musk and Dorsey want to ‘delete all IP law’; The Washington Post, April 15, 2025

 

Analysis by 
 and 
with research by 
 , The Washington Post; Why Musk and Dorsey want to ‘delete all IP law’

"Jack Dorsey, the co-founder of Twitter and CEO of Square, posted a cryptic and drastic demand on Elon Musk’s X over the weekend: “delete all IP law.” The post drew a quick reply from Mr. X himself: “I agree.”

Musk’s laconic response amplified Dorsey’s post to his 220 million followers and sparked a debate that drew in a cast of characters including Epic Games CEO Tim Sweeney, tech lawyer and former vice presidential candidate Nicole Shanahan, novelist Walter Kirn, evolutionary psychologist Geoffrey Miller and the technologist and early Twitter developer Evan Henshaw-Plath, a.k.a. Rabble, among others...

Serious policy idea or not, the concord between Dorsey and Musk highlights how the debate over AI and copyright law is coming to a head in Silicon Valley.

How it’s resolved will have major ramifications for the tech companies, creative people and their livelihoods and the overall AI race."

Wednesday, November 2, 2016

Patent rights key to ensuring access to medication; Trib Live, 10/24/16

Robert A. Freeman, Trib Live; Patent rights key to ensuring access to medication:
" A United Nations panel recently released disastrous policy recommendations designed to increase access to medicines in developing countries. The panel ignored obvious solutions.
Secretary General Ban Ki-Moon originally tasked the UN High-Level Panel on Access to Medicines with remedying the “policy incoherence” between intellectual property rights and drug access. The panel predictably — and wrongly — viewed IP protections as a barrier to access rather than a bridge to medical innovation.
Undermining IP rights will not help patients in developing countries access medicines.
A 2016 Foreign Affairs study sought to determine whether strong patent protections increase the prices of drugs to developing countries. It found that patents were not key drivers of higher expenditures."